Skip to Main Content

Paper Details

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
Nat Commun
33
2022
28, Anti-SARS-CoV-2 monoclonal antibodies, COVID-19, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 RNA, bamlanivimab, nasopharyngeal
Author NameAffiliation
Eric S DaarLundquist Institute at Harbor-university of california los angeles Medical Center
David A WohlUniversity of North Carolina at Chapel Hill School of Medicine
William A FischerUniversity of North Carolina at Chapel Hill School of Medicine
Joseph J EronUniversity of North Carolina at Chapel Hill School of Medicine
Judith S CurrierDavid Geffen School of Medicine at University of California los angeles
Judith S CurrierDavid Geffen School of Medicine at University of California los angeles
Davey M SmithUniversity of California
  • 1 - 7

Datasets